We show that RIP3 controls NASH development in a Caspase-8-dependent manner by a pathway involving activation of Jun-(N)-terminal kinase and thus might represent a promising target for future therapeutic strategies in patients with chronic metabolic liver disease. Here, MAPK8 is linked to metabolic dysfunction-associated steatohepatitis.